DOC Stock Analysis: Healthpeak Properties | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 14.817m USD | 12M Return: 29.6% | US42250P1030 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 129M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Healthpeak Properties, Inc. (NYSE: DOC) is an S&P 500 REIT that owns, operates, and develops healthcare-focused real estate across the United States. Founded in 1985 and headquartered in Denver, Colorado, the company is structured as an umbrella partnership REIT, with substantially all assets and operations held through its operating subsidiary, Healthpeak OP. The company qualifies as a self-administered REIT and is incorporated in Maryland.
Healthpeaks diversified portfolio is organized around three core asset classes: outpatient medical, lab, and continuing care retirement community (CCRC) real estate. Its outpatient medical and lab segments include outpatient medical buildings, hospitals, and lab buildings, while CCRC properties are operated through RIDEA (REIT Investment Diversification and Empowerment Act) structures, which permit the REIT to share in operating revenue rather than limiting it to rental income. Non-reportable segments include a joint-venture interest in senior housing assets, loans receivable, and a preferred equity investment.
As of September 30, 2025, the companys investment portfolio, including properties held through unconsolidated joint ventures, consisted of interests in 703 properties: 530 outpatient medical, 139 lab, 15 CCRC, and 19 properties classified as other non-reportable. With a large-cap market capitalization of approximately $14 billion, Healthpeak operates within the Health Care REITs sub-industry, a segment whose performance is generally tied to demographic trends such as the aging U.S. population and rising demand for outpatient and life-sciences facilities.
- Lab segment occupancy pressured by biotech funding pullback
- Interest rate sensitivity impacts cost of capital and FFO growth
- Aging demographics fuel outpatient medical tenant demand
| Net Income: 253.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -4.92 > 1.0 |
| NWC/Revenue: 29.21% < 20% (prev -18.62%; Δ 47.83% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.23b > Net Income 253.7m |
| Net Debt (8.98b) to EBITDA (1.78b): 5.04 < 3 |
| Current Ratio: 1.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (689.9m) vs 12m ago -1.04% < -2% |
| Gross Margin: 2.53% > 18% (prev 60.42%; Δ -57.88% > 0.5%) |
| Asset Turnover: 14.22% > 50% (prev 14.11%; Δ 0.11% > 0%) |
| Interest Coverage Ratio: 2.03 > 6 (EBIT TTM 685.2m / Interest Expense TTM 337.0m) |
| A: 0.04 (Total Current Assets 1.89b - Total Current Liabilities 1.03b) / Total Assets 21.7b |
| B: -0.27 (Retained Earnings -5.95b / Total Assets 21.7b) |
| C: 0.03 (EBIT TTM 685.2m / Avg Total Assets 20.7b) |
| D: 0.64 (Book Value of Equity 7.84b / Total Liabilities 12.2b) |
| Altman-Z'' = 0.26 = B |
| DSRI: 0.32 (Receivables 261.4m/785.3m, Revenue 2.95b/2.80b) |
| GMI: 23.85 (GM 60.42% / 2.53%) |
| AQI: 0.96 (AQ_t 0.89 / AQ_t-1 0.93) |
| SGI: 1.06 (Revenue 2.95b / 2.80b) |
| TATA: -0.05 (NI 253.7m - CFO 1.23b) / TA 21.7b) |
| Beneish M = 17.13 (Cap -4..+1) = D |
As of August 17, 2026, the stock is trading at USD 20.79 with a total of 2,001,248 shares traded. Over the past week, the price has changed by -2.90%, over one month by -6.47%, over three months by +7.69% and over the past year by +29.64%.
Current recommended Stop Loss: 20.10 (which is 3.3% or 1.4 ATR below the current price).
Healthpeak Properties has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy DOC.
- StrongBuy: 10
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.6 | 8.5% |
P/E Trailing = 61.4706
P/E Forward = 142.8571
P/S = 5.023
P/B = 1.8819
P/EG = 4.0809
Revenue TTM = 2.95b USD
EBIT TTM = 685.2m USD
EBITDA TTM = 1.78b USD
Long Term Debt = 8.54b USD (from longTermDebt, last quarter)
Short Term Debt = 750.4m USD (from shortTermDebt, last quarter)
Debt = 10.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 288.2m
Net Debt = 8.98b USD (calculated: Debt 10.6b - CCE 1.63b)
Enterprise Value = 23.8b USD (14.8b + Debt 10.6b - CCE 1.63b)
Interest Coverage Ratio = 2.03 (Ebit TTM 685.2m / Interest Expense TTM 337.0m)
EV/FCF = 80.34x (Enterprise Value 23.8b / FCF TTM 296.2m)
FCF Yield = 1.24% (FCF TTM 296.2m / Enterprise Value 23.8b)
FCF Margin = 10.04% (FCF TTM 296.2m / Revenue TTM 2.95b)
Net Margin = 8.60% (Net Income TTM 253.7m / Revenue TTM 2.95b)
Gross Margin = 2.53% ((Revenue TTM 2.95b - Cost of Revenue TTM 2.88b) / Revenue TTM)
Gross Margin QoQ = 56.83% (prev -19.97%)
Tobins Q-Ratio = 1.10 (Enterprise Value 23.8b / Total Assets 21.7b)
Interest Expense / Debt = 3.18% (Interest Expense 337.0m / Debt 10.6b)
Taxrate = 1.32% (3.67m / 278.5m)
NOPAT = 676.2m (EBIT 685.2m * (1 - 1.32%))
Current Ratio = 1.84 (Total Current Assets 1.89b / Total Current Liabilities 1.03b)
Debt / Equity = 1.35 (Debt 10.6b / totalStockholderEquity, last quarter 7.84b)
Debt / EBITDA = 5.04 (Net Debt 8.98b / EBITDA 1.78b)
Debt / FCF = 30.32 (Net Debt 8.98b / FCF TTM 296.2m)
Total Stockholder Equity = 7.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.22% (Net Income 253.7m / Total Assets 21.7b)
RoE = 3.30% (Net Income TTM 253.7m / Total Stockholder Equity 7.69b)
RoCE = 4.22% (EBIT 685.2m / Capital Employed (Equity 7.69b + L.T.Debt 8.54b))
RoIC = 3.18% (NOPAT 676.2m / Invested Capital 21.3b)
WACC = 5.18% (E(14.8b)/V(25.4b) * Re(6.64%) + D(10.6b)/V(25.4b) * Rd(3.18%) * (1-Tc(0.01)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 42.49 | Cagr: 6.31%
[DCF] Terminal Value 73.10% ; FCFF base≈675.6m ; Y1≈592.4m ; Y5≈478.7m
[DCF] Fair Price = N/A (negative equity: EV 7.68b - Net Debt 8.98b = -1.30b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.16 | # QB: 0
Revenue Correlation: 94.83 | Revenue CAGR: 12.70% | SUE: 1.85 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.06 | Chg30d=N/A | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=0.41 | Chg30d=-26.36% | Revisions=-25% | GrowthEPS=+938.5% | GrowthRev=+4.4%
EPS next Year (2027-12-31): EPS=-0.15 | Chg30d=-200.00% | Revisions=-25% | GrowthEPS=-137.0% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: -50% (up=0, down=3)